MIODx is advancing VerifyDx, an oncology testing platform that uses a multiplexed assay to interrogate expression levels of biomarkers implicated in cancer aggressiveness. The company started with a prostate cancer test and plans to launch additional tests for colon, lung, and kidney cancers. MIODx is also developing and has intellectual property related to sequencing of T cell repertoires. Led by COO and co-founder Sean Givens and CEO Allen Northrup, the company is pursuing clinical validation and commercialization. MIODx closed a seed financing to fund its near-term plans. The proceeds will be used to complete the clinical utility study for its VerifyDx Prostate Cancer test and begin commercialization.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

May 2016